ArticleDrug design, development and therapy2026
Population Pharmacokinetics and Dose Optimization of Vancomycin in Adult Cancer Patients.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to develop a population pharmacokinetics (PPK) model of vancomycin (VAN) in adult cancer patients, to identify the factors affecting VAN pharmacokinetics, and to perform different dosing simulations in order to propose optimized individually dosing regimens. Patients and Methods: A total of 303 samples from 132 adult patients (age range, 18 to 85 years; 48 females and 84 males) diagnosed with cancer and receiving vancomycin were enrolled. A PPK model was developed using NONMEM 7.5. Goodness-of-fit (GOF) plots, visual predictive check (VPC), and bootstrap were used as internal evaluation. External evaluation of the final model was performed. The dosing regimen was optimized using Monte Carlo dose simulations. The ratio of the area under the concentration-time curve up to 24 h to minimum inhibitory concentration (AUC Results: A two-compartment pharmacokinetic model with zero-order absorption and first-order elimination described the VAN PK data best. In the final model, CL (L/h)=9.12×e Conclusion: Unlike previous population pharmacokinetic studies that relied on serum creatinine or creatinine clearance, this study incorporated blood urea nitrogen (BUN) and age as the key covariates for vancomycin clearance in adult cancer patients. Based on these covariates and MIC, a validated PPK model enabled individualized dosing to achieve efficacy targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.